Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Berubicin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    CNS Pharma Unveils Strategy For High-Value Neurology & Oncology
    CNS Pharma Unveils Strategy For High-Value Neurology & Oncology

    11 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-11/cns-pharmaceuticals-launches-new-corporate-strategy-focused-on-building-a-high-value-neurology-and-o

    PHARMIWEB
    11 Mar 2026
    Share Share
    CNS Pharmaceuticals Updates on Berubicin Study in GBM
    CNS Pharmaceuticals Updates on Berubicin Study in GBM

    25 Nov 2024

    // ACCESSWIRE

    https://www.accesswire.com/946585/cns-pharmaceuticals-presents-update-from-ongoing-potentially-pivotal-study-of-berubicin-compared-with-lomustine-in-adult-patients-with-recurrent-gbm-who-grade-iv-after-failure-of-standard-first-line-therapy

    ACCESSWIRE
    25 Nov 2024
    Share Share
    CNS Achieves Completion of Enrollment in Pivotal Study of Berubicin
    CNS Achieves Completion of Enrollment in Pivotal Study of Berubicin

    17 Jan 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=825674&lang=en

    ACCESSWIRE
    17 Jan 2024
    Share Share
    CNS Announces Efficacy and Safety Data in Potentially Pivotal Study of Berubicin
    CNS Announces Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

    18 Dec 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=817849&lang=en

    ACCESSWIRE
    18 Dec 2023
    Share Share
    CNS Pharma Presents Safety Data from Pivotal Study Evaluating Berubicin
    CNS Pharma Presents Safety Data from Pivotal Study Evaluating Berubicin

    22 Nov 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=808204&lang=en

    ACCESSWIRE
    22 Nov 2023
    Share Share
    CNS Pharmaceuticals' Ongoing Potentially Pivotal Study of Berubicin
    CNS Pharmaceuticals' Ongoing Potentially Pivotal Study of Berubicin

    11 Oct 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=791819&lang=en

    ACCESSWIRE
    11 Oct 2023
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.